Completed
Buprenorphine Dosing Interval
Led by National Institute on Drug Abuse (NIDA) · Updated on 2005-08-17
N/A
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.
CONDITIONS
Official Title
Buprenorphine Dosing Interval - 5
Who Can Participate
Eligibility Criteria
You may qualify if you...
M/F ages 21-50. Opiate dependence according to DSM-IV critera. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.
You will not qualify if you...
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.
Trial Site Locations
Total: 1 location
1
Friends Research Institute
Los Angeles, California, United States, 90025
Status Unknown
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here